Wistar rats received an hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, a halogenated pyrrole designated PD 123244-15, orally by gavage for 14 days at 10, 50, 150, 300, and 600 mg/kg. Doses of 150-600 mg/kg caused death and marked systemic toxicity involving stomach, esophagus, liver, gonads, lymphoid tissues, and skeletal muscle. Histopathologic findings included hyperkeratosis in esophagus and forestomach, increased hepatic mitotic activity, ovarian follicular necrosis, testicular atrophy and arrested spermatogenesis, and skeletal muscle necrosis and regeneration. Elevated serum aspartate aminotransferase correlated with muscle necrosis and hepatocellular damage. Marked systemic effects associated with high plasma concentrations were consistent with toxicity defined for other HMG-CoA reductase inhibitors, with the exception of pathologic alterations in the esophagus and ovaries. Direct mucosal irritation may have contributed to forestomach and esophageal lesions induced by this halogenated pyrrole.
INTRODUCTION
A halogenated pyrrole (PD 123244-15), described chemically as (+)-(R*,R*)-3,4-dibromo-2-(4-fluorophenyl)-0,6-dihydroxy-5-(l -methylethyl)-1Hpyrrole-1-hexanoic acid monosodium salt; Fig. 1 ) is an inhibitor of hydroxymethylglutaryl~oenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in de novo cholesterol biosynthesis. HMG-CoA reductase activity is found in numerous tissues, with highest concentrations localized in liver. Inhibition of hepatic cholesterol synthesis results in an upregulation of low-density lipoprotein (LDL) receptors, thereby lowering circulating LDL-cholesterol concentrations (9) . In addition to decreasing cholesterol synthesis, HMG-CoA reductase inhibition leads to decreased cellular production of ubiquinone and dolichols (1, 4, 11) . Rats have been used by the pharmaceutical industry for short-term and chronic administration of numerous reductase inhibitors, and toxicity data can be readily compared across compounds. This experiment also served to establish a range of doses appropriate for rats in longer-term studies. HMG-CoA reductase inhibitors are known to induce target organ toxicity at high doses in both rodents and nonrodents. Specific mechanisms of toxicity in target organs are yet to be defined. However, hepatocellular atypia and necrosis and hyperkeratosis of rodent nonglandular stomach have been minimized or prevented by co-administration of mevalonate, confirming that these changes are related to pharmacologic action (8) .
MATERIALS AND METHODS
Animals. Male and female albino Wistar rats (Crl: (WI)BR), were obtained from Charles River Breeding Laboratories (Portage, MI). At study initiation, animals were 7 wk of age and weighed 90-120 g. This experiment was conducted in accordance with current guidelines for animal welfare (NIH Publication 86-23, 1985; Animal Welfare Act, 1966, as amended in 1970, 1976, and 1985 [Code of Federal Register 9: Parts 1, 2, and 3]). Animals were housed in individual cages and maintained in clean, climate-controlled quarters with an alternating 12-hr cycle of light and dark. Rats received 180 g of Purina Rodent Chow #5002 weekly and were given water ad libitum. Animals were fasted by removal of food during the evening prior to collection of serum samples and tissues. Administration of Test Compound. Groups of 10 Wistar rats/sex were given PD 123244-15 by daily gavage in 0.5% methylcellulose at 10, 50, 150, 300, and 600 mg/kg for 2 wk. An additional group of 10 rats/sex received methylcellulose vehicle. Laboratory Procedures. Plasma drug levels were determined for 5 animals/sex/group from blood samples obtained by orbital sinus puncture on Day 14 2 hr postdosing. Drug concentrations were determined by high-pressure liquid chromatography.
All animals were euthanatized by ether inhalation. Blood samples were obtained by cardiac puncture at necropsy from 10 animals/sex/group. Serum biochemical determinations were evaluated by standard laboratory procedures and included glucose, phosphorus, calcium, cholesterol, total bilirubin, total protein, albumin, globulin, urea nitrogen, creatinine, chloride, sodium, potassium, aspartate and alanine aminotransferase (AST and ALT), and lactic dehydrogenase. Peripheral hematologic determinations were performed to evaluate the leukon, erythron, and platelets. Marrow smears were prepared from femoral marrow of each rat. Urinalyses were performed on urine samples obtained 24-72 hr prior to termination. Arithmetic means, standard deviations, and standard errors were calculated from numerical data generated in this study using standard mathematical formulae. All parameters were compared between groups at the end of 1 wk or at the end of the 2-wk dosing period. A probability level of 0.99 was used for the criterion of significance by applying the 2-tailed Student's t-test. Only parameters with significant alterations are reported in this paper.
Pathology. Necropsies were completed on all animals. Organ weights were obtained for thyroids, liver, heart, spleen, kidneys, adrenals, and gonads on animals surviving to termination, and tissues were fixed in 10% buffered formalin, routinely processed, sectioned, and stained with hematoxylin and eosin (H&E). Gross and histopathologic evaluation of the stomach included evaluation of the forestomach (nonglandular stomach), which comprised approximately one-third of the stomach lining contiguous with distal esophagus. The forestomach had a stratified epithelial mucosa devoid of gastric glands. Gastric glandular mucosa was also evaluated.
RESULTS

Clinical Observations
Nine of 10 males and 9/ 10 females given 600 mg/ kg died during the first week. The remaining male and female died during the second week. All rats given 300 mg/kg died, with the majority of deaths occurring during the second week. Four of 10 males and 10/ 10 females given 150 mg/kg died, with all deaths occurring during the second week. There were no deaths at 10 and 50 mg/kg. Clinical signs common in both males and females at doses of 150, 300, and 600 mg/kg included emaciation, hypoactivity, rough pelage, transient salivation, urine scald, epiphora, and ataxia. Soft feces or diarrhea were noted in groups receiving 50 mg/kg and above.
Compared to controls, the mean body weights of 150-mg/kg males and females were decreased 26 and 32%, respectively, at the end of week 1 (Table  I) . Similarly, the mean body weights of 300-mg/kg males and females were decreased 40 and 27%, respectively, at the end of week 1. Food consumption was reduced significantly compared to controls in 150-and 300-mg/kg males and in 50and 150-mg/ kg females at the end of week 1 (Table I) .
Pathology and Pharmacokinetics
Due to high mortality, serum biochemical parameters and organ weights were not measured and body weights were not analyzed statistically in the 2 highest dose groups. At termination of dosing, serum AST and ALT activities were significantly elevated in 50-mg/kg females compared to controls ( Fig. 2 and Table II ). Serum ALT was significantly elevated in surviving 150-mg/kg males but not in 50-mg/kg males. Three of the 6 150-mg/kg males surviving to study termination had moderate (3-4-fold) increases in AST, although group mean values were not elevated compared to controls. Absolute liver weights, mean liver-to-body weight, and liver-tobrain weight ratios were increased significantly in females administered 50 mg/kg (range of increase from 18 to 32%; Table I ). Males administered 150 mg/kg and surviving to study termination had a 52% increase in liver-to-body weight ratio. Mean plasma drug concentrations measured in 10-, 50-, and 150mg/kg animals surviving to termination were 0.8, 6.3, and 23.7 pg/ml, respectively.
The majority of significant alterations seen at gross necropsy involved the forestomach in animals administered 150 mg/kg and above. Incidence and severity of gross lesions in the forestomach were dose-dependent and included hyperkeratosis, desquamation, and thickening of the mucosa. A few animals given 300 and 600 mg/kg had erosions or hemorrhage of the glandular gastric mucosa. One male each given 50 and 150 mg/kg had multifocal pallor of the axial and/or appendicular skeletal muscle.
Dose-dependent histopathologic lesions induced by PD 123244-15 were present in the esophagus, stomach, liver, ovaries, thymus, spleen, lymph nodes, Peyer's patches, bone marrow, skeletal muscle, lung, submaxillary salivary gland, kidney, testes, and epididymides (Table III) . Of the organs listed, only the liver had drug-induced changes in absolute TABLE IL-Serum levels of selected enzymes in rats treated with PD 123244-15 for 2 wk.&dquo; a a Group mean values tor A51, AL and alkahne phosphatase (ALP) with standard error ln parentheses. b Biochemical analyses were not performed in females at 150 mg/kg and animals at higher doses due to poor survival, as outlined in text. * Significantly different from vehicle control (p < 0.01). and relative weights as detailed above. At the lowest dose administered (10 mg/kg), the liver and stomach were the primary target organs. Livers from the majority of rats given 150 mg/kg or greater were marked by prominent, multifocal to diffuse anisokaryosis and periportal to panlobular hepatocellular vacuolation and hypertrophy (Fig. 3 ). Single-cell necrosis of hepatocytes was minimal at 50 mg/kg and minimal to mild in affected animals given 150 mg/kg and above. Livers at all doses had TABLE III.&horbar;Incidence of histopathologic changes in rats given PD-123244-15. a n = 20 males and females. b n = 10 females. x310. a minimal (10-and 50-mg/kg rats) to mild (150-, 300-, and 600-mg/kg rats) increase in numbers of mitotic figures (Fig. 3 ). Miminal to mild mucosal hyperkeratosis of nonglandular stomach was noted at 10 mg/kg. In all higher dose groups, mild to marked mucosal hyperkeratosis, parakeratosis, and epithelial hyperplasia were present (Fig. 4) . In markedly hyperkeratotic areas, layers of squames achieved a thickness equal to that of the tunica muscularis. Mild to marked epithelial dysplasia and necrosis occurred with a dose-dependent increase in severity in groups re-ceiving 50 mg/kg and above. Focal ulceration was present in nonglandular stomach in 1/20 rats at 300and 600-mg/kg doses.
Hyperkeratosis, parakeratosis, and epithelial hyperplasia were present in esophageal mucosa of drugtreated animals (Fig. 5 ). The severity of mucosal changes in the esophagus was comparable in 150-, 300-, and 600-mg/kg dose groups. In each affected animal, the degree of esophageal mucosal thickening was less than that seen in the nonglandular stomach. Degeneration and necrosis of skeletal muscle occurred in rats given 150 mg/kg or more and corre- (Fig. 6 ). Severity of skeletal muscle change was dose-related and most widely disseminated in rats surviving beyond the first week of dosing. In the majority of affected animals, skeletal muscle necrosis was accompanied by myofiber regeneration and granulomatous myositis.
A dose-related increase in extent and incidence of follicular necrosis was seen in ovaries of rats at all doses (Table III and Fig. 7 ). Furthermore, necrosis of corpora lutea was seen in several females given 50 mg/kg and above. Parenchymal atrophy and arrested spermatogenesis were present in testes of rats at 150 mg/kg and above. Epididymal ducts epithelium and the keratinized layer. B) Male given 10 mg/kg PD 123244-15 has mild diffuse hyperkeratosis (h) and focal mucosal ulceration (arrowhead). The submucosa (s) is edematous and infiltrated by moderate numbers of inflammatory cells. C) Male given 50 mg/kg has marked diffuse hyperkeratosis and moderate diffuse acanthosis (arrowhead) of stratified squamous epithelium. D) Male given 150 mg/kg has severe diffuse hyperkeratosis and acanthosis of mucosa. Prominent irregular fronds of epithelial cells extend deeply into the submucosa. H&E. x 50.
FIG. 6. -Quadriceps muscle of a male rat given 150 mg/ kg for 2 wk demonstrates marked variation in fiber size associated with myofiber degeneration/necrosis. Endo- mysium is infiltrated with scattered macrophages. Regenerative fibers have conspicuous rows of central nuclei (arrowheads). H&E.
x 130.
of rats with testicular lesions contained spermatozoa and cell debris. Dose-related lymphoid necrosis and/ or depletion in thymus, spleen, Peyer's patches, and mesenteric lymph nodes occurred at 150 mg/kg and above.
DISCUSSION
The liver was an expected target organ of this reductase inhibitor, as it is the primary site of cholesterol synthesis in the body, and liver effects are reported with other HMG-CoA reductase inhibitors administered to rodents (4, 10) . Inhibition of HMG-CoA reductase in rats leads to marked enzyme induction (14) minimizing decreases in serum cholesterol levels in this species (3) . Areas of cytoplasmic vacuolation and hepatocellular swelling seen in H&E-stained liver sections have been associated with smooth endoplasmic reticulum proliferation that occurs with enzyme induction (14) . The eosphageal alterations seen in rats given 50 mg/kg and above are unique findings in this toxicity study. Hyperkeratosis of the esophageal mucosa in rats with PD 123244-15 treatment is a relevant finding to human safety. Features of gastric and esophageal lesions suggest that direct contact of drug is important. In this oral study, forestomach and esophagus were the only keratinized stratified squamous epithelia affected. Parenteral administration of a pharmacologically active form of simvastatin in rodents produced no forestomach hyperplasia or acanthosis at doses that caused such changes when simvastatin was administered by gavage (4) . Physical contact may cause sufficient irritation to induce hyperkeratosis, or physical contact may be necessary to achieve high local drug concentrations resulting in pharmacologically mediated changes in gastric and esophageal tissues (6) . There is evidence that forestomach hyperkeratosis, hyperplasia, and acanthosis are a consequence of reductase inhibition, as forestomach effects are common across structurally diverse reductase inhibitors (10) . Also, mevalonic acid co-administration lessens the severity of forestomach changes (10) , pointing to the importance of enzyme inhibition in the induction of forestomach changes.
Pathologic alterations in ovaries have not been previously reported with reductase inhibitor administration to rodents. Follicular necrosis was an acute effect occurring with high frequency even in 300and 600-mg/kg animals that died after only a few days of dosing. The mechanism of follicular necrosis with this compound has not been determined.
Rhabdomyolysis, as noted in rats treated with PD 123244-15, has been reported clinically with lovastatin most commonly in cases where there were concomitant therapies with gemfibrozil and/or cyclosporine and other immunosuppressive agents (7, 13, 16) . In some patients with rhabdomyolysis, elevations of the muscle-specific isozyme of creatine kinase occurred in association with high plasma levels of the reductase inhibitor. Muscle biopsy revealed inflammation and muscle fiber degeneration similar to changes seen with PD 123244-15 (2, 5, 13) . Reductase inhibitors may cause muscle degeneration due to their effects on membrane glycoproteins or alterations of the mitochondrial respiratory chain (5, 12) . In the present study, serum biochemistries were not available for animals with the most severe muscle pathology. However, at lower doses, there was a strong correlation between elevations in serum AST activity and muscle necrosis and/or hepatocellular injury.
The in vitro potency of this compound has been compared to that of other reductase inhibitors in a CoA reductase inhibition screen measuring direct conversion of D,L-[14C]HMG-CoA to mevalonic acid. PD 123244-15 had an Icso of 0.028 Am compared to the reference compound compactin (a fungal metabolite) with an IC51 of 0.030 Am and lovastatin with an lC50 of 0.020 ~M (15) . In the present study, mean plasma drug concentrations demonstrated dose proportionality orders of a magnitude higher than levels achieved with comparable doses of other reductase inhibitors, and one can assume that high tissue concentrations were also achieved. The mucosal drug exposures and high plasma concentrations attained in this 2-wk experiment with doses of PD 123244-15 up to 600 mg/kg were probably factors leading to previously undescribed pathology in the esophagus and ovaries.
